Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.

Christopher J. DiBlasio, Jessica Hammett, John B. Malcolm, Beth A. Judge, Jamie H. Womack, Matthew C. Kincade, Mitchell L. Ogles, John G. Mancini, Anthony Patterson, Robert Wake, Ithaar H. Derweesh

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

OBJECTIVE: Androgen deprivation therapy (ADT) remains a widely utilized modality for treatment of localized and advanced prostate cancer. While ADT-induced alterations in testosterone have demonstrated impacts on quality of life, the effects on mental health remain ill-defined. We investigated the prevalence of de novo psychiatric illness and predictive factors following ADT induction for prostate cancer. MATERIALS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between 1/1989-7/2005, excluding men receiving only neoadjuvant ADT. Variables included age, race, body mass index, prostate-specific antigen (PSA), Gleason sum, clinical stage, ADT type (medical/surgical) and schedule (continuous/intermittent), and presence of pre-ADT and newly diagnosed psychiatric illness. The cohort was divided into three groups for analysis: pre-ADT psychiatric illness, de novo psychiatric illness, and no psychiatric illness. Data analysis utilized statistical software with p < 0.05 considered significant. RESULTS: Three-hundred and ninety-five patients with a mean age of 71.7 years at ADT initiation were analyzed. Thirty-four men (8.6%) were diagnosed with pre-ADT psychiatric illness. At mean follow-up of 87.4 months, 101 (27.9%) men were diagnosed with de novo psychiatric illness, most commonly including: depression (n = 57; 56.4%), dementia (n = 14; 13.9%), and anxiety (n = 9; 8.9%). On multivariate analysis, increasing pre-ADT PSA was predictive of post-ADT anxiety (p = 0.01). Overall and disease-specific survival outcomes were similar between groups. CONCLUSIONS: De novo psychiatric illness was identified in 27.9% of men. While no predictive factors were identified for de novo psychiatric illness, increasing PSA was associated with de novo anxiety. Prospective investigation using validated instruments is requisite to further delineate the relationship between ADT and psychiatric health.

Original languageEnglish (US)
JournalThe Canadian journal of urology
Volume15
Issue number5
StatePublished - Jan 1 2008

Fingerprint

Androgens
Psychiatry
Prostatic Neoplasms
Therapeutics
Prostate-Specific Antigen
Anxiety
Statistical Data Interpretation
Dementia
Testosterone
Appointments and Schedules
Mental Health
Body Mass Index
Software
Multivariate Analysis
Quality of Life
Depression

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

DiBlasio, C. J., Hammett, J., Malcolm, J. B., Judge, B. A., Womack, J. H., Kincade, M. C., ... Derweesh, I. H. (2008). Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. The Canadian journal of urology, 15(5).

Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. / DiBlasio, Christopher J.; Hammett, Jessica; Malcolm, John B.; Judge, Beth A.; Womack, Jamie H.; Kincade, Matthew C.; Ogles, Mitchell L.; Mancini, John G.; Patterson, Anthony; Wake, Robert; Derweesh, Ithaar H.

In: The Canadian journal of urology, Vol. 15, No. 5, 01.01.2008.

Research output: Contribution to journalArticle

DiBlasio, CJ, Hammett, J, Malcolm, JB, Judge, BA, Womack, JH, Kincade, MC, Ogles, ML, Mancini, JG, Patterson, A, Wake, R & Derweesh, IH 2008, 'Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.', The Canadian journal of urology, vol. 15, no. 5.
DiBlasio, Christopher J. ; Hammett, Jessica ; Malcolm, John B. ; Judge, Beth A. ; Womack, Jamie H. ; Kincade, Matthew C. ; Ogles, Mitchell L. ; Mancini, John G. ; Patterson, Anthony ; Wake, Robert ; Derweesh, Ithaar H. / Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. In: The Canadian journal of urology. 2008 ; Vol. 15, No. 5.
@article{6bcad347a9684533b1b8c1c7b0272a7d,
title = "Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.",
abstract = "OBJECTIVE: Androgen deprivation therapy (ADT) remains a widely utilized modality for treatment of localized and advanced prostate cancer. While ADT-induced alterations in testosterone have demonstrated impacts on quality of life, the effects on mental health remain ill-defined. We investigated the prevalence of de novo psychiatric illness and predictive factors following ADT induction for prostate cancer. MATERIALS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between 1/1989-7/2005, excluding men receiving only neoadjuvant ADT. Variables included age, race, body mass index, prostate-specific antigen (PSA), Gleason sum, clinical stage, ADT type (medical/surgical) and schedule (continuous/intermittent), and presence of pre-ADT and newly diagnosed psychiatric illness. The cohort was divided into three groups for analysis: pre-ADT psychiatric illness, de novo psychiatric illness, and no psychiatric illness. Data analysis utilized statistical software with p < 0.05 considered significant. RESULTS: Three-hundred and ninety-five patients with a mean age of 71.7 years at ADT initiation were analyzed. Thirty-four men (8.6{\%}) were diagnosed with pre-ADT psychiatric illness. At mean follow-up of 87.4 months, 101 (27.9{\%}) men were diagnosed with de novo psychiatric illness, most commonly including: depression (n = 57; 56.4{\%}), dementia (n = 14; 13.9{\%}), and anxiety (n = 9; 8.9{\%}). On multivariate analysis, increasing pre-ADT PSA was predictive of post-ADT anxiety (p = 0.01). Overall and disease-specific survival outcomes were similar between groups. CONCLUSIONS: De novo psychiatric illness was identified in 27.9{\%} of men. While no predictive factors were identified for de novo psychiatric illness, increasing PSA was associated with de novo anxiety. Prospective investigation using validated instruments is requisite to further delineate the relationship between ADT and psychiatric health.",
author = "DiBlasio, {Christopher J.} and Jessica Hammett and Malcolm, {John B.} and Judge, {Beth A.} and Womack, {Jamie H.} and Kincade, {Matthew C.} and Ogles, {Mitchell L.} and Mancini, {John G.} and Anthony Patterson and Robert Wake and Derweesh, {Ithaar H.}",
year = "2008",
month = "1",
day = "1",
language = "English (US)",
volume = "15",
journal = "Canadian Journal of Urology",
issn = "1195-9479",
publisher = "Canadian Journal of Urology",
number = "5",

}

TY - JOUR

T1 - Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.

AU - DiBlasio, Christopher J.

AU - Hammett, Jessica

AU - Malcolm, John B.

AU - Judge, Beth A.

AU - Womack, Jamie H.

AU - Kincade, Matthew C.

AU - Ogles, Mitchell L.

AU - Mancini, John G.

AU - Patterson, Anthony

AU - Wake, Robert

AU - Derweesh, Ithaar H.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - OBJECTIVE: Androgen deprivation therapy (ADT) remains a widely utilized modality for treatment of localized and advanced prostate cancer. While ADT-induced alterations in testosterone have demonstrated impacts on quality of life, the effects on mental health remain ill-defined. We investigated the prevalence of de novo psychiatric illness and predictive factors following ADT induction for prostate cancer. MATERIALS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between 1/1989-7/2005, excluding men receiving only neoadjuvant ADT. Variables included age, race, body mass index, prostate-specific antigen (PSA), Gleason sum, clinical stage, ADT type (medical/surgical) and schedule (continuous/intermittent), and presence of pre-ADT and newly diagnosed psychiatric illness. The cohort was divided into three groups for analysis: pre-ADT psychiatric illness, de novo psychiatric illness, and no psychiatric illness. Data analysis utilized statistical software with p < 0.05 considered significant. RESULTS: Three-hundred and ninety-five patients with a mean age of 71.7 years at ADT initiation were analyzed. Thirty-four men (8.6%) were diagnosed with pre-ADT psychiatric illness. At mean follow-up of 87.4 months, 101 (27.9%) men were diagnosed with de novo psychiatric illness, most commonly including: depression (n = 57; 56.4%), dementia (n = 14; 13.9%), and anxiety (n = 9; 8.9%). On multivariate analysis, increasing pre-ADT PSA was predictive of post-ADT anxiety (p = 0.01). Overall and disease-specific survival outcomes were similar between groups. CONCLUSIONS: De novo psychiatric illness was identified in 27.9% of men. While no predictive factors were identified for de novo psychiatric illness, increasing PSA was associated with de novo anxiety. Prospective investigation using validated instruments is requisite to further delineate the relationship between ADT and psychiatric health.

AB - OBJECTIVE: Androgen deprivation therapy (ADT) remains a widely utilized modality for treatment of localized and advanced prostate cancer. While ADT-induced alterations in testosterone have demonstrated impacts on quality of life, the effects on mental health remain ill-defined. We investigated the prevalence of de novo psychiatric illness and predictive factors following ADT induction for prostate cancer. MATERIALS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between 1/1989-7/2005, excluding men receiving only neoadjuvant ADT. Variables included age, race, body mass index, prostate-specific antigen (PSA), Gleason sum, clinical stage, ADT type (medical/surgical) and schedule (continuous/intermittent), and presence of pre-ADT and newly diagnosed psychiatric illness. The cohort was divided into three groups for analysis: pre-ADT psychiatric illness, de novo psychiatric illness, and no psychiatric illness. Data analysis utilized statistical software with p < 0.05 considered significant. RESULTS: Three-hundred and ninety-five patients with a mean age of 71.7 years at ADT initiation were analyzed. Thirty-four men (8.6%) were diagnosed with pre-ADT psychiatric illness. At mean follow-up of 87.4 months, 101 (27.9%) men were diagnosed with de novo psychiatric illness, most commonly including: depression (n = 57; 56.4%), dementia (n = 14; 13.9%), and anxiety (n = 9; 8.9%). On multivariate analysis, increasing pre-ADT PSA was predictive of post-ADT anxiety (p = 0.01). Overall and disease-specific survival outcomes were similar between groups. CONCLUSIONS: De novo psychiatric illness was identified in 27.9% of men. While no predictive factors were identified for de novo psychiatric illness, increasing PSA was associated with de novo anxiety. Prospective investigation using validated instruments is requisite to further delineate the relationship between ADT and psychiatric health.

UR - http://www.scopus.com/inward/record.url?scp=55249098909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249098909&partnerID=8YFLogxK

M3 - Article

C2 - 18814813

AN - SCOPUS:55249098909

VL - 15

JO - Canadian Journal of Urology

JF - Canadian Journal of Urology

SN - 1195-9479

IS - 5

ER -